32082-17-0

Usage

Uses

Used in Pharmaceutical Industry:
1-methyl-3-oxocyclobutane-1-carbonitrile is used as an intermediate in the production of various pharmaceuticals. Its unique structure and functional groups make it a valuable building block for the synthesis of new drug molecules.
Used in Agrochemical Industry:
1-methyl-3-oxocyclobutane-1-carbonitrile is also used as an intermediate in the production of agrochemicals. Its potential applications in this industry include the development of new pesticides and other agricultural chemicals.
Used in Medicinal Chemistry Research:
Due to its potential biological activities and pharmacological properties, 1-methyl-3-oxocyclobutane-1-carbonitrile is used as a research compound in medicinal chemistry. Scientists study its interactions with biological targets to explore its potential as a therapeutic agent.
Used in Drug Development:
1-methyl-3-oxocyclobutane-1-carbonitrile is employed in drug development processes as a key component in the synthesis of new drug candidates. Its presence in various pharmaceuticals and agrochemicals highlights its importance in the development of innovative and effective treatments.

Upstream product

• 15760-35-7 3-methylenecyclobutanecarbonitrile 
• 32082-16-9 1-methyl-3-methylenecyclobutane-1-carbonitrile 

Relevant academic research and scientific papers

PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES

A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.